Medtech layoffs are picking up as 2024 draws to a close. Sean Whooley, Associate Editor, and Chris Newmarker, Editor-in-Chief The medical device industry is closing out the year with a fresh round of layoffs. At this point, MassDevice has reported on more than 22,000 medtech job cuts across the industry since mid-2022. (Have a tip […]
Boston Scientific
Boston Scientific has a new EMEA president
Boston Scientific (NYSE:BSX) today announced the appointment of Xavier Bertrand as president and SVP for the EMEA region. Mike Mahoney, the company’s chair and CEO, said on the company’s third-quarter earnings call in October that Bertrand, previously the VP of Peripheral Interventions, EMEA, was selected to lead the business in Europe, the Middle East and […]
Report: Boston Scientific takes step toward Minnesota expansion
Finance & Commerce reports that Boston Scientific took the next step toward a massive expansion in Maple Grove, Minnesota. The report said the Maple Grove Planning Commission issued its support for a proposed building addition at the company’s Weaver Lake Road campus. This project reportedly adds 84,000 square feet of manufacturing and support spaces to […]
Boston Scientific shares positive Acurate Prime XL TAVR data
Boston Scientific (NYSE:BSX) shared data highlighting the safety and efficacy of its Acurate Prime aortic valve system. Dr. Raj Makkar of Cedar-Sinai Medical Center presented data at PCR London Valves 2024. The 30-day outcomes came from the first combined dataset analysis evaluating the safety and efficacy of the Acurate prime aortic valve platform — exclusively […]
Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology
Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera Oncology for an undisclosed amount. Intera Oncology develops the Intera 3000 hepatic artery infusion pump and floxuridine, a chemotherapy drug. Both hold FDA approval. The pump administers hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by […]
Boston Scientific Watchman FLX demonstrates superiority to anticoagulants in study
Boston Scientific (NYSE:BSX) announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device. The OPTION global trial compared Watchman FLX, a left atrial appendage closure (LAAC) device, to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with […]
Boston Scientific finalizes $3.7B acquisition of Axonics
Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX). The Marlborough, Massachusetts–based medtech giant priced the deal at $71 per share in cash, representing an equity value of $3.7 billion and an enterprise value of $3.3 billion. The acquisition expands Boston Scientific’s urology offerings by adding […]
Boston Scientific resumes study of pulse field ablation as first-line AFib therapy
Boston Scientific (NYSE: BSX) is resuming its “Avant Guard” study of pulse field ablation as a first-line therapy for persistent atrial fibrillation (AFib). The device developer paused the trial last month, with CEO Mike Mahoney citing the need to “assess a few unanticipated observations.” Boston Scientific said it did not halt the trial due to […]
Boston Scientific to acquire Cortex and its cardiac mapping tech
Boston Scientific (NYSE: BSX) announced today that it will purchase Ajax Health’s Cortex and its FDA-cleared OptiMap system to guide physicians performing ablation procedures to treat AFib Financial terms of the deal were not disclosed. Boston Scientific expects to complete the transaction in the first half of 2025, subject to customary closing conditions. “We believe […]
The biggest cardiovascular tech stories from TCT 2024
The 2024 edition of the Transcatheter Cardiovascular Therapeutics (TCT) conference once again highlighted significant innovations in cardiovascular care. This year’s event in Washington, D.C., featured company updates on all types of technologies, including heart valves, access and closure devices, drug-eluting implants, intravascular lithotripsy (IVL), renal denervation (RDN) and more. Some of the biggest names in […]
Boston Scientific Acurate neo2 TAVR misses primary endpoint in IDE trial
Boston Scientific (NYSE:BSX) today announced that a study of its Acurate neo2 aortic valve system missed its primary endpoint. The ACURATE IDE study evaluated Acurate neo2, a transcatheter aortic valve replacement (TAVR) system, in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery. Investigators presented […]